Intralipid treatment for women with reproductive failures
- PMID: 32567756
- DOI: 10.1111/aji.13290
Intralipid treatment for women with reproductive failures
Abstract
Does intravenous intralipid treatment for reproductive failure enhance live births? The answer to this question is yes, BUT only in patients that have a diagnosis of recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) loss AND demonstrate elevated NK (natural killer) cell density in their endometrial biopsy. Live birth rates have been reported between 33% and 42% among women displaying elevated NK activity with a diagnosis of RIF and 75% and 91% among women experiencing RPL after intralipid infusion. When the pregnancy outcomes of women with a history of reproductive failure and elevated NK cells treated with intralipid were evaluated, the overall live birth rate per cycle of treatment was 61%. The results of published studies suggest that intralipid can be used successfully as a therapeutic option to modulate abnormal NK activity in women with reproductive problems.
Keywords: RIF; RPL; intralipid; reproductive failure.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Immunotherapy to improve pregnancy outcome in women with abnormal natural killer cell levels/activity and recurrent miscarriage or implantation failure: A systematic review and meta-analysis.J Reprod Immunol. 2020 Nov;142:103189. doi: 10.1016/j.jri.2020.103189. Epub 2020 Aug 22. J Reprod Immunol. 2020. PMID: 32889304
-
Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer.Clin Exp Obstet Gynecol. 2016;43(1):14-5. Clin Exp Obstet Gynecol. 2016. PMID: 27048011
-
Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation.J Reprod Immunol. 2018 Nov;130:18-22. doi: 10.1016/j.jri.2018.09.050. Epub 2018 Sep 24. J Reprod Immunol. 2018. PMID: 30286362
-
Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion.Arch Gynecol Obstet. 2016 Jul;294(1):29-39. doi: 10.1007/s00404-015-3922-8. Epub 2015 Dec 15. Arch Gynecol Obstet. 2016. PMID: 26671484 Clinical Trial.
-
Intralipid therapy and adverse reproductive outcome: is there any evidence?Reprod Fertil. 2021 Jun 3;2(3):173-186. doi: 10.1530/RAF-20-0052. eCollection 2021 Jul. Reprod Fertil. 2021. PMID: 35118388 Free PMC article.
Cited by
-
Immune Cell Functionality during Decidualization and Potential Clinical Application.Life (Basel). 2023 Apr 27;13(5):1097. doi: 10.3390/life13051097. Life (Basel). 2023. PMID: 37240742 Free PMC article. Review.
-
Endometrial scratching and intralipid treatment-no general recommendations.Front Reprod Health. 2024 Nov 27;6:1505842. doi: 10.3389/frph.2024.1505842. eCollection 2024. Front Reprod Health. 2024. PMID: 39665034 Free PMC article.
-
Effect of IVIG therapy on pregnant women with unexplained recurrent spontaneous abortion: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2024 Aug 14;15:1381461. doi: 10.3389/fendo.2024.1381461. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39205682 Free PMC article.
-
Exploring the Immunological Aspects and Treatments of Recurrent Pregnancy Loss and Recurrent Implantation Failure.Int J Mol Sci. 2025 Feb 3;26(3):1295. doi: 10.3390/ijms26031295. Int J Mol Sci. 2025. PMID: 39941063 Free PMC article. Review.
-
Prevalence of Antiphospholipid Antibody Syndrome Among Patients with Recurrent Pregnancy Loss: Impact of the Revised 2023 ACR/EULAR Antiphospholipid Syndrome Criteria.J Clin Med. 2024 Dec 17;13(24):7698. doi: 10.3390/jcm13247698. J Clin Med. 2024. PMID: 39768619 Free PMC article.
References
REFERENCES
-
- Clark DA. The power of observation. Am J Reprod Immunol. 2011;66:71-75.
-
- Ford HB, Schust D. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009;2:76-83.
-
- Roussev RG, Acacio B, Ng SC, Coulam CB. Duration of Intralipid’s suppressive effect on NK cell’s functional activity. Am J Reprod Immunol. 2008;60:258-263.
-
- Roussev RG, Ng SC, Coulam CB. Natural Killer cell functional activity suppression by Intravenous Immunoglobulin, Intralipid and soluble Human Leukocyte Antigen-G. Am J Reprod Immunol. 2007;57:262-269.
-
- Niavarani S, Lawson C, Bakos O, et al. Lipid accumulation impairs natural killer cell cytotoxicity and tumor control in the postoperative period. BMC Cancer. 2019;19:823-828.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical